CD44 and cancer: We previously investigated the histological diversity and molecular characteristics of GC and found that GCs with histological diversity on the tumor invasive front have a significantly poorer prognosis and are associated with cancer stem cell-related molecules (CD44, CD133, ALDH1), receptor tyrosine kinase molecules (HER2, EGFR, c-MET), and HP infection [7].